Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.56 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | ACP3 | P15309 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7649264 | 0.87 | SLC6A2 (0.43) | SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL8983761 | 0.85 | SLC6A2 (0.42) | SLC6A2SLC6A4 | |
| SCHEMBL23848782 | 0.84 | SLC6A2 (0.47) | SLC6A2SLC6A4 | |
| SCHEMBL3660818 | 0.82 | SLC6A2 (0.58) | SLC6A2SLC6A4TACR1ACP3 | |
| SCHEMBL25501912 | 0.81 | SLC6A2 (0.44) | SLC6A2SLC6A4 | |
| SCHEMBL3725941 | 0.81 | SLC6A2 (0.86) | SLC6A2SLC6A4 | |
| SCHEMBL3719834 | 0.81 | SLC6A2 (0.86) | SLC6A2SLC6A4 | |
| SCHEMBL3715944 | 0.81 | SLC6A2 (0.86) | SLC6A2SLC6A4 | |
| SCHEMBL3719829 | 0.81 | SLC6A2 (0.86) | SLC6A2SLC6A4 | |
| SCHEMBL13152467 | 0.81 | SLC6A2 (0.86) | SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230146127-A1 | 3-DIARYLMETHYLENES AND USES THEREOF | ATUX ISKAY LLC | 2023-05-11 | — | — | US | disclosed |
| WO-2021188949-A1 | 3-DIARYLMETHYLENES AND USES THEREOF | ATUX ISKAY LLC (US) | 2021-09-23 | — | — | WO | disclosed |
| US-8258306-B2 | Glycine transporter-1 inhibitors | AMGEN INC. (US) | 2012-09-04 | — | — | US | disclosed |
| US-20100298341-A1 | Glycine Transporter-1 Inhibitors | AMGEN INC. | 2010-11-25 | — | — | US | disclosed |
| EP-2231601-A2 | GLYCINE TRANSPORTER-1 INHIBITORS | Amgen, Inc (US) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009075857-A2 | GLYCINE TRANSPORTER-1 INHIBITORS | AMGEN INC. (US) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230146127-A1 | 3-DIARYLMETHYLENES AND USES THEREOF | MYC, MYCBP, FOXO1 | SLC6A2 4182/4885SLC6A4 4333/4885HTR6 3590/4885 |
| US-20100298341-A1 | Glycine Transporter-1 Inhibitors | SLC18A2, SLC7A11, SLC6A5 | SLC6A2 7/4885SLC6A4 16/4885HTR6 338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.